Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAXCYTE, INC.MXCT · Entity 6608 | Chief Financial Officer | March 25, 2022 | March 29, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAXCYTE, INC.
Report date March 25, 2022 · Filed March 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2032-03-24 | Direct | 142,000 |
Reported balance
After 2022-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-25 · Grant · Acquired 142,000 · Balance 142,000 F1: 25% of the shares underlying this option vest on March 25, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option vest on March 25, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2022 Filed Mar 29, 2022 16:16 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantEmployee Stock Option (right to buy) · Derivative | 142,000 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-22-021464 · doc4.xml · derivative · entry 1 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Stock · 142,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: 25% of the shares underlying this option vest on March 25, 2023 and the remaining 75% vest in 36 equal monthly installments thereafter, subject to the reporting person's continuous service with the Issuer at each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 37,306 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · derivative · entry 9 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 37,306 shares Expires 2030-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. F5 · derivative.exercise_date: One-sixteenth (1/16th) of the shares underlying this option vested on December 7, 2020, and the remainder vested or shall vest monthly in forty-five (45) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 37,306 | $12.08 | $450,656.48 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · nonDerivative · entry 6 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 37,306 | $4.42 | $164,892.52 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · nonDerivative · entry 5 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 61,591 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · derivative · entry 8 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,306 Underlying: Common Stock · 61,591 shares Expires 2030-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. F5 · derivative.exercise_date: One-sixteenth (1/16th) of the shares underlying this option vested on December 7, 2020, and the remainder vested or shall vest monthly in forty-five (45) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 61,591 | $12.16 | $748,946.56 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · nonDerivative · entry 4 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 15, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 61,591 | $4.42 | $272,232.22 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · nonDerivative · entry 3 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 51,103 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · derivative · entry 7 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,098,897 Underlying: Common Stock · 51,103 shares Expires 2030-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. F5 · derivative.exercise_date: One-sixteenth (1/16th) of the shares underlying this option vested on December 7, 2020, and the remainder vested or shall vest monthly in forty-five (45) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | SaleCommon Stock | 51,103 | $12.66 | $646,963.98 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · nonDerivative · entry 2 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 19:12 UTC | MAXCYTE, INC. MXCT · Entity 6608 | Exercise / conversionCommon Stock | 51,103 | $4.42 | $225,875.26 |
DisclosureSEC source: 0001209191-21-064884 · doc4.xml · nonDerivative · entry 1 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 17:18 UTC | MAXCYTE, INC. MXCT · Entity 6608 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.63 | $0.00 |
DisclosureSEC source: 0001209191-21-050948 · doc4.xml · derivative · entry 1 Murphy Amanda Louise · CIK 0001875169 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-08-09 F1 · derivative.exercise_date: 25% of the shares underlying the option vest on August 9, 2022 and the remaining shares underlying the option vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.